Addison Pritchett
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Addison Pritchett has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- James Steven Leeder
Division of Clinical Pharmacology, Toxicology & Therapeutic Innovation, Department of Pediatrics Children's Mercy Kansas City Missouri USA
4 shared publications - Allison Dunn
Center for Translational Medicine University of Maryland School of Pharmacy Baltimore MD USA
2 shared publications - Brooke L. Fridley
Children's Mercy Kansas City Missouri USA
2 shared publications - Catherine Koertje2 shared publications
- George Ekow Quaye
Biostatistics and Computational Biology Core, Center for Population Health and Outcomes Research, Children’s Mercy Kansas City, Kansas City, MO 64108, USA
2 shared publications - Harpreet Singh Gill
Research Informatics, Children's Mercy Hospital, Kansas City, MO, United States
2 shared publications
Latest Publications
- Open Access
- 29 October 2026
- Published by JMIR Publications Inc. in Journal of Medical Internet Research
- Vol. 28, e104511
Identifying Burnout in Pediatric Clinicians Using Wearable Biometric Data: Development and Feasibility Study
Background: Addressing the burnout epidemic among health care providers remains one of the foremost challenges of modern health care systems. Past researchers have turned to passively gathered biometric data from wearable devices to identify key variables that predict burnout. However, this has resulted in limited success. Objective: This pilot and feasibility study aimed to test the feasibility and accuracy of developing an Extreme Gradient Boosting machine learning model to classify health care providers as being at higher or lower risk of burnout based on their biometric data. Methods: We conducted a 3-month pilot and feasibility study where health care providers self-reported burnout every 6 weeks and wore a Garmin Venu 3 smartwatch to collect continuous biometric data. Participants were recruited from 3 pediatric urgent care sites and an inpatient hospitalist division of a pediatric health care system. We had a final sample of 41 participants who met our inclusion criteria requiring completion of burnout measurements at 2 of the 3 time points and having worn the watch for at least 70% of the study period. Participants were asked to wear the Garmin watch continuously over the course of the study. Burnout self-report surveys were delivered via email. Our main outcome was burnout as measured using the Maslach Burnout Inventory–Human Services Survey. The measure consists of 3 subscales that together constitute burnout: emotional exhaustion, depersonalization, and reduced personal efficacy. Results: First, we found evidence of feasibility for wearable watches to be used in situ for health care providers to gather data passively for the purposes of classifying burnout. A total of 82% (51/62) of participants met our criteria of wearing the watch 70% of the time, with 66% (41/62) having corresponding burnout scores to be included in analyses. Second, our machine learning model achieved strong overall performance in identifying risk of burnout, with strong sensitivity and specificity, demonstrating that biometric data collected using wearable devices can accurately predict burnout. Conclusions: Our evidence of feasibility offers promising results for a passive method of data collection to be used for classifying burnout risk in other health care settings. Furthermore, the strong performance of our machine learning model provides a foundational step toward improving an organization’s ability to respond and mitigate burnout through thoughtful intervention strategies.
- 29 October 2026
- Published by JMIR Publications Inc. in Journal of Medical Internet Research
- Vol. 28, e104511
Open AccessIdentifying Burnout in Pediatric Clinicians Using Wearable Biometric Data: Development and Feasibility Study
Background: Addressing the burnout epidemic among health care providers remains one of the foremost challenges of modern health care systems. Past researchers have turned to passively gathered biometric data from wearable devices to identify key variables that predict burnout. However, this has resulted in limited success. Objective: This pilot and feasibility study aimed to test the feasibility and accuracy of developing an Extreme Gradient Boosting machine learning model to classify health care providers as being at higher or lower risk of burnout based on their biometric data. Methods: We conducted a 3-month pilot and feasibility study where health care providers self-reported burnout every 6 weeks and wore a Garmin Venu 3 smartwatch to collect continuous biometric data. Participants were recruited from 3 pediatric urgent care sites and an inpatient hospitalist division of a pediatric health care system. We had a final sample of 41 participants who met our inclusion criteria requiring completion of burnout measurements at 2 of the 3 time points and having worn the watch for at least 70% of the study period. Participants were asked to wear the Garmin watch continuously over the course of the study. Burnout self-report surveys were delivered via email. Our main outcome was burnout as measured using the Maslach Burnout Inventory–Human Services Survey. The measure consists of 3 subscales that together constitute burnout: emotional exhaustion, depersonalization, and reduced personal efficacy. Results: First, we found evidence of feasibility for wearable watches to be used in situ for health care providers to gather data passively for the purposes of classifying burnout. A total of 82% (51/62) of participants met our criteria of wearing the watch 70% of the time, with 66% (41/62) having corresponding burnout scores to be included in analyses. Second, our machine learning model achieved strong overall performance in identifying risk of burnout, with strong sensitivity and specificity, demonstrating that biometric data collected using wearable devices can accurately predict burnout. Conclusions: Our evidence of feasibility offers promising results for a passive method of data collection to be used for classifying burnout risk in other health care settings. Furthermore, the strong performance of our machine learning model provides a foundational step toward improving an organization’s ability to respond and mitigate burnout through thoughtful intervention strategies.
- Open Access
- 11 September 2026
- Published by Wiley in Clinical and Translational Science
- Vol. 19 (9) , e70724
Posaconazole Target Attainment in Critically Ill Children: A 15‐Year Single‐Center Retrospective Analysis
Posaconazole is a triazole antifungal agent used for prophylaxis and treatment of invasive fungal diseases. Posaconazole has high inter‐individual variability in dose‐exposure relationship and benefits from therapeutic drug monitoring (TDM). Adult studies report particularly high rates of subtherapeutic exposure among intensive care unit (ICU) patients related to changes in physiology during critical illness. The rates of subtherapeutic posaconazole exposure among critically ill children in ICU's are unknown. This single‐center retrospective analysis at a large freestanding children's hospital used TDM results from 2010 to 2025 obtained while patients were undergoing care in a pediatric ICU. Therapeutic targets were ≥ 1.0 mg/L for treatment of infection and ≥ 0.7 mg/L for prophylaxis. A general linear mixed model (GLMM) was used to assess factors which differed between instances with therapeutic and subtherapeutic posaconazole concentrations. Sixty‐two posaconazole concentrations from 30 ICU patients were analyzed, of which 24 (39%) concentrations were below target based on their therapeutic indication. Both univariate analysis and stepwise GLMM identified an association between liquid formulation and subtherapeutic targets (OR 29.6, CI 2.2–398.2, p = 0.01). However, even among critically ill children with IV posaconazole administration 13/46 (28%) measured concentrations remained subtherapeutic. Rates of subtherapeutic posaconazole exposure among critically ill children are high, though lower than reported from adult ICU cohorts. Liquid formulation use was associated with subtherapeutic concentrations, however appreciable instances of subtherapeutic exposure persist in patients receiving IV administration. Further research is needed to identify characteristics of critically ill patients at risk of subtherapeutic posaconazole exposure and to develop strategies to optimize attainment of appropriate medication exposure.
- 11 September 2026
- Published by Wiley in Clinical and Translational Science
- Vol. 19 (9) , e70724
Open AccessPosaconazole Target Attainment in Critically Ill Children: A 15‐Year Single‐Center Retrospective Analysis
Posaconazole is a triazole antifungal agent used for prophylaxis and treatment of invasive fungal diseases. Posaconazole has high inter‐individual variability in dose‐exposure relationship and benefits from therapeutic drug monitoring (TDM). Adult studies report particularly high rates of subtherapeutic exposure among intensive care unit (ICU) patients related to changes in physiology during critical illness. The rates of subtherapeutic posaconazole exposure among critically ill children in ICU's are unknown. This single‐center retrospective analysis at a large freestanding children's hospital used TDM results from 2010 to 2025 obtained while patients were undergoing care in a pediatric ICU. Therapeutic targets were ≥ 1.0 mg/L for treatment of infection and ≥ 0.7 mg/L for prophylaxis. A general linear mixed model (GLMM) was used to assess factors which differed between instances with therapeutic and subtherapeutic posaconazole concentrations. Sixty‐two posaconazole concentrations from 30 ICU patients were analyzed, of which 24 (39%) concentrations were below target based on their therapeutic indication. Both univariate analysis and stepwise GLMM identified an association between liquid formulation and subtherapeutic targets (OR 29.6, CI 2.2–398.2, p = 0.01). However, even among critically ill children with IV posaconazole administration 13/46 (28%) measured concentrations remained subtherapeutic. Rates of subtherapeutic posaconazole exposure among critically ill children are high, though lower than reported from adult ICU cohorts. Liquid formulation use was associated with subtherapeutic concentrations, however appreciable instances of subtherapeutic exposure persist in patients receiving IV administration. Further research is needed to identify characteristics of critically ill patients at risk of subtherapeutic posaconazole exposure and to develop strategies to optimize attainment of appropriate medication exposure.
- Open Access
- 12 June 2026
- Published by JMIR Publications Inc. in JMIR Preprints
Identifying Burnout in Pediatric Clinicians Using Wearable Biometric Data (Preprint)
BACKGROUND Addressing the burnout epidemic among health care providers remains one of the foremost challenges of modern health care systems. Past researchers have turned to passively gathered biometric data from wearable devices to identify key variables that predict burnout. However, this has resulted in limited success. OBJECTIVE This study aims to test the feasibility and accuracy of using a machine learning approach to classifying health care providers as at higher or lower risk of burnout based upon biometric data. METHODS We conducted a 3-month study where health care providers self-reported burnout every 6 weeks and wore a Garmin Venu 3 smartwatch to collect continuous biometric data. Participants were recruited from 3 pediatric urgent care sites and an inpatient hospitalist division of a pediatric health care system. We had a final sample of 41 participants who met our inclusion criteria requiring completion of burnout measurements at two of the three timepoints and having worn the watch for at least 70% of the study period. Participants were asked to wear the Garmin watch continuously over the course of the study. Burnout self-report surveys were delivered via email. Our main outcome was burnout as measured by the Maslach Burnout Inventory (MBI-HSS). The measure consists of three subscales that together constitute burnout: emotional exhaustion, depersonalization, and reduced personal efficacy. RESULTS First, we found evidence of feasibility for wearable watches to be used in situ for health care providers to gather data passively for the purposes of classifying burnout. 73% of participants met our criteria of wearing the watch 70% of the time. Second, our machine learning model achieved strong overall performance in identifying risk of burnout with strong sensitivity and specificity, demonstrating that biometric data collected by wearable devices can accurately predict burnout. CONCLUSIONS Our evidence of feasibility offers promising results for a passive method of data collection to be used for classifying burnout risk in other health care settings. Further, the strong performance of our machine learning model provides a foundational step towards improving an organization’s ability to respond and mitigate burnout through thoughtful intervention strategies.
- 12 June 2026
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessIdentifying Burnout in Pediatric Clinicians Using Wearable Biometric Data (Preprint)
BACKGROUND Addressing the burnout epidemic among health care providers remains one of the foremost challenges of modern health care systems. Past researchers have turned to passively gathered biometric data from wearable devices to identify key variables that predict burnout. However, this has resulted in limited success. OBJECTIVE This study aims to test the feasibility and accuracy of using a machine learning approach to classifying health care providers as at higher or lower risk of burnout based upon biometric data. METHODS We conducted a 3-month study where health care providers self-reported burnout every 6 weeks and wore a Garmin Venu 3 smartwatch to collect continuous biometric data. Participants were recruited from 3 pediatric urgent care sites and an inpatient hospitalist division of a pediatric health care system. We had a final sample of 41 participants who met our inclusion criteria requiring completion of burnout measurements at two of the three timepoints and having worn the watch for at least 70% of the study period. Participants were asked to wear the Garmin watch continuously over the course of the study. Burnout self-report surveys were delivered via email. Our main outcome was burnout as measured by the Maslach Burnout Inventory (MBI-HSS). The measure consists of three subscales that together constitute burnout: emotional exhaustion, depersonalization, and reduced personal efficacy. RESULTS First, we found evidence of feasibility for wearable watches to be used in situ for health care providers to gather data passively for the purposes of classifying burnout. 73% of participants met our criteria of wearing the watch 70% of the time. Second, our machine learning model achieved strong overall performance in identifying risk of burnout with strong sensitivity and specificity, demonstrating that biometric data collected by wearable devices can accurately predict burnout. CONCLUSIONS Our evidence of feasibility offers promising results for a passive method of data collection to be used for classifying burnout risk in other health care settings. Further, the strong performance of our machine learning model provides a foundational step towards improving an organization’s ability to respond and mitigate burnout through thoughtful intervention strategies.
- 29 May 2026
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 66 (6) , e70212
Response to Letter to the Editor from Madhuri Tribhuvan and Shashikant N. Phatke
- 29 May 2026
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 66 (6) , e70212
Response to Letter to the Editor from Madhuri Tribhuvan and Shashikant N. Phatke
- Open Access
- 29 March 2026
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 66 (4) , e70168
Understanding Atomoxetine Exposure Variability in Children and Adolescents With ADHD Through Population Pharmacokinetics
Atomoxetine, a selective norepinephrine reuptake inhibitor, is a nonstimulant alternative to treat attention‐deficit/hyperactivity disorder in children and adolescents. Atomoxetine exposure is highly variable due to cytochrome P450 polymorphism; however, the impact of these genetic variations has not been adequately characterized in the pediatric population. A population pharmacokinetic (PK) model was developed to evaluate steady‐state atomoxetine exposures after oral administration in a large, heterogeneous population of children and adolescents with different metabolic phenotypes. Due to the highly variable and complex absorption between subjects and occasions, a two‐stage approach was implemented, treating each participant/occasion as a separate individual. First, the individual atomoxetine parameters were estimated using a one‐compartment distribution model with zero‐order duration into a depot compartment followed by first‐order absorption into the central compartment with linear elimination. Next, population‐level parameters were obtained, and covariate analysis was performed. Using actual body weight, relative bioavailability based on CYP2D6 or CYP2C19 phenotype, and CYP2D6 clearance effects in the model reduced the variability from 81.6% to 64.5% and 92.4% to 75.5% for apparent volume and apparent clearance, respectively. The final model showed adequate precision in PK parameters and accuracy in exposure metrics. Following prospective validation, this model could be used to provide clinicians with individualized dosing targets when prescribing atomoxetine to children and adolescents based on their genetic disposition.
- 29 March 2026
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 66 (4) , e70168
Open AccessUnderstanding Atomoxetine Exposure Variability in Children and Adolescents With ADHD Through Population Pharmacokinetics
Atomoxetine, a selective norepinephrine reuptake inhibitor, is a nonstimulant alternative to treat attention‐deficit/hyperactivity disorder in children and adolescents. Atomoxetine exposure is highly variable due to cytochrome P450 polymorphism; however, the impact of these genetic variations has not been adequately characterized in the pediatric population. A population pharmacokinetic (PK) model was developed to evaluate steady‐state atomoxetine exposures after oral administration in a large, heterogeneous population of children and adolescents with different metabolic phenotypes. Due to the highly variable and complex absorption between subjects and occasions, a two‐stage approach was implemented, treating each participant/occasion as a separate individual. First, the individual atomoxetine parameters were estimated using a one‐compartment distribution model with zero‐order duration into a depot compartment followed by first‐order absorption into the central compartment with linear elimination. Next, population‐level parameters were obtained, and covariate analysis was performed. Using actual body weight, relative bioavailability based on CYP2D6 or CYP2C19 phenotype, and CYP2D6 clearance effects in the model reduced the variability from 81.6% to 64.5% and 92.4% to 75.5% for apparent volume and apparent clearance, respectively. The final model showed adequate precision in PK parameters and accuracy in exposure metrics. Following prospective validation, this model could be used to provide clinicians with individualized dosing targets when prescribing atomoxetine to children and adolescents based on their genetic disposition.